Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698568 · ClinicalTrials.gov registry record · Phase 3
Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,460
- Enrollment target
NCT00698568 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 7,460 participants.
The verdict
NCT00698568, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,460 participants
- Enrollment target
Study Summary
This study will evaluate, versus a placebo, the safety of Herpes simplex candidate vaccine with adjuvant in initially HSV seropositive or seronegative subjects who have no genital herpes disease.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Herpes simplex candidate vaccine- adjuvanted GSK 208141
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,460 participants |
| Start Date | 1996-10 |
| Est. Completion | 1999-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698568
The ClinicalTrials.gov registry entry for NCT00698568 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7,460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00698568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00698568 about?
NCT00698568 is a clinical study titled "Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects". This study will evaluate, versus a placebo, the safety of Herpes simplex candidate vaccine with adjuvant in initially HSV seropositive or seronegative subjects who have no genital herpes disease.
What is the current status of trial NCT00698568?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,460 participants. The study started on 1996-10. Estimated completion is 1999-04.
What interventions are being tested in trial NCT00698568?
The interventions under investigation include: Placebo (BIOLOGICAL), Herpes simplex candidate vaccine- adjuvanted GSK 208141 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00698568?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.